Zydus Completes Merger, Acquires Control of Asserthio Holdings Inc. Following Transaction
Zydus Lifesciences Limited has successfully completed a significant acquisition transaction, finalizing the merger of its subsidiary, Zara Merger Sub Inc., into Asserthio Holdings Inc. Following this completion, Asserthio Holdings, a specialized oncology pharmaceutical company, has become a wholly owned subsidiary of Zydus. As part of this transition, the common stocks of Asserthio are no longer listed or traded on the Nasdaq Global Market.The merger process involved the acquisition of all outstanding shares of common stock of Asserthio. This transaction marks the culmination of efforts to gain full control over the specialized pharmaceutical entity.
Transaction Details and Company Profiles
Asserthio Holdings Inc., which is headquartered in Lake Forest, Illinois, is a U.S.-based specialty oncology pharmaceutical company. Its primary product, ROLVEDON® (eflapregastim-xnst), is an FDA approved long acting G-CSF biologic designed for preventing febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy.The following table outlines the details of the entities involved in the amalgamation:
| Particulars | Zara Merger Sub Inc. | Asserthio Holdings Inc. |
|---|---|---|
| Type | Acquisition subsidiary of Zydus | Nasdaq listed pharmaceutical company |
| Incorporation/Registration | Incorporated April 24, 2026 | Registered in Delaware, USA |
| Area of Business | N/A | Specialty oncology pharmaceutical; commercial capability for marketing and distribution of differentiated oncology products. |
| Key Metric (CY ended Dec 31, 2025) | N/A | Adjusted turnover of USD 68.23 million for ROLVEDON® |
Strategic Rationale and Consideration Offered
The rationale behind the merger was to acquire outstanding shares and gain complete control over Asserthio as a wholly owned subsidiary of Zydus Lifesciences Limited.In the transaction, an offer price of USD 23.50 per share in cash was offered for Asserthio common stock. This consideration represented a total amount of USD 166.33 million on a fully diluted basis.
ZYDUSLIFE Stock Price Movement
Shares of Zydus Lifesciences Limited today slipped by 0.67% to settle at ₹1078.7. The stock saw a volume of 1.049 million shares traded as the market closed.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.